^
Association details:
Biomarker:ATM mutation + IGH mutation
Cancer:Chronic Lymphocytic Leukemia
Regimen:BR (bendamustine + Rituxan (rituximab))
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE

Published date:
05/17/2018
Excerpt:
To analyze progression-free survival (PFS) according to the presence of genetic defects in CLL patients treated with front line FCR or BR regimen...we performed subsequent analyses separately according to the IGHV status; (c) clear negative impact of ATM mutations in patients with mut-IGHV (25 vs. 56 m in ATM-wt patients; P = 0.017)...